313 related articles for article (PubMed ID: 34363461)
1. Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients.
Mekinian A; Biard L; Dagna L; Novikov P; Salvarani C; Espitia O; Sciascia S; Michaud M; Lambert M; Hernández-Rodríguez J; Schleinitz N; Awisat A; Puéchal X; Aouba A; Munoz Pons H; Smitienko I; Gaultier JB; Le Mouel E; Benhamou Y; Perlat A; Jego P; Goulenok T; Sacre K; Lioger B; Hassold N; Broner J; Dufrost V; Sene T; Seguier J; Maurier F; Berthier S; Belot A; Frikha F; Denis G; Audemard-Verger A; Kone Pault I; Humbert S; Woaye-Hune P; Tomelleri A; Baldissera E; Kuwana M; Lo Gullo A; Gaches F; Zeminsky P; Galli E; Alvarado M; Boiardi L; Muratore F; Vautier M; Campochiaro C; Moiseev S; Cacoub P; Fain O; Saadoun D;
Rheumatology (Oxford); 2022 Apr; 61(4):1376-1384. PubMed ID: 34363461
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Biological-Targeted Treatments in Takayasu Arteritis: Multicenter, Retrospective Study of 49 Patients.
Mekinian A; Comarmond C; Resche-Rigon M; Mirault T; Kahn JE; Lambert M; Sibilia J; Néel A; Cohen P; Hie M; Berthier S; Marie I; Lavigne C; Anne Vandenhende M; Muller G; Amoura Z; Devilliers H; Abad S; Hamidou M; Guillevin L; Dhote R; Godeau B; Messas E; Cacoub P; Fain O; Saadoun D;
Circulation; 2015 Nov; 132(18):1693-700. PubMed ID: 26354797
[TBL] [Abstract][Full Text] [Related]
3. Biologic treatments in Takayasu's Arteritis: A comparative study of tumor necrosis factor inhibitors and tocilizumab.
Alibaz-Oner F; Kaymaz-Tahra S; Bayındır Ö; Yazici A; Ince B; Kalkan K; Kanıtez NA; Kocaer SB; Yasar Bilge NS; Omma A; Durak E; Ilgın C; Akar S; Kaşifoğlu T; Önen F; Emmungil H; İnanç M; Cefle A; Aksu K; Keser G; Direskeneli H
Semin Arthritis Rheum; 2021 Dec; 51(6):1224-1229. PubMed ID: 34706312
[TBL] [Abstract][Full Text] [Related]
4. Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study.
Mekinian A; Biard L; Lorenzo D; Novikov PI; Salvarani C; Espitia O; Sciascia S; Michaud M; Lambert M; Hernández-Rodríguez J; Schleinitz N; Awisat A; Puechal X; Aouba A; Munoz Pons H; Smitienko I; Gaultier JB; Edwige LM; Benhamou Y; Perlat A; Jego P; Goulenok T; Sacre K; Lioger B; Hassold N; Broner J; Dufrost V; Sené T; Seguier J; Maurier F; Berthier S; Belot A; Frikha F; Denis G; Audemard-Verger A; Koné-Paut I; Humbert S; Woaye-Hune P; Tomelleri A; Baldissera EM; Kuwana M; Lo Gullo A; Mukuchyan V; Dellal A; Gaches F; Zeminsky P; Galli E; Alvarado M; Boiardi L; Muratore F; Vautier M; Campochiaro C; Moiseev S; Vieira M; Cacoub P; Fain O; Saadoun D;
RMD Open; 2023 Jun; 9(2):. PubMed ID: 37321669
[TBL] [Abstract][Full Text] [Related]
5. Serial analysis of clinical and imaging indices reveals prolonged efficacy of TNF-α and IL-6 receptor targeted therapies in refractory Takayasu arteritis.
Youngstein T; Peters JE; Hamdulay SS; Mewar D; Price-Forbes A; Lloyd M; Jeffery R; Kinderlerer AR; Mason JC
Clin Exp Rheumatol; 2014; 32(3 Suppl 82):S11-8. PubMed ID: 24093733
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study.
Nakaoka Y; Isobe M; Tanaka Y; Ishii T; Ooka S; Niiro H; Tamura N; Banno S; Yoshifuji H; Sakata Y; Kawakami A; Atsumi T; Furuta S; Kohsaka H; Suzuki K; Hara R; Maejima Y; Tsukamoto H; Takasaki Y; Yamashita K; Okada N; Yamakido S; Takei S; Yokota S; Nishimoto N
Rheumatology (Oxford); 2020 Sep; 59(9):2427-2434. PubMed ID: 31951279
[TBL] [Abstract][Full Text] [Related]
7. [Tocilizumab for refractory Takayasu arteritis with aortic aneurysm].
Frikha F; Garbaa S; Bouattour Y; Snoussi M; Loukil H; Ben Salah R; Bahloul Z
J Med Vasc; 2019 May; 44(3):237-239. PubMed ID: 31029281
[TBL] [Abstract][Full Text] [Related]
8. A multicentre, large-scale, observational study of tocilizumab in patients with Takayasu arteritis in Japan: The ACTEMRA® (ACT)-Bridge study.
Harigai M; Miyamae T; Hashimoto H; Yoshida A; Yamashita K; Nakaoka Y
Mod Rheumatol; 2023 Aug; 33(5):998-1006. PubMed ID: 36057089
[TBL] [Abstract][Full Text] [Related]
9. Anti-Tumor Necrosis Factor α versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema: A Multicenter Study from the French Uveitis Network.
Leclercq M; Andrillon A; Maalouf G; Sève P; Bielefeld P; Gueudry J; Sené T; Moulinet T; Rouvière B; Sène D; Desbois AC; Domont F; Touhami S; El Chamieh C; Cacoub P; Bodaghi B; Biard L; Saadoun D
Ophthalmology; 2022 May; 129(5):520-529. PubMed ID: 34793830
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of tocilizumab in Takayasu arteritis: Multicenter retrospective study of 46 patients.
Mekinian A; Resche-Rigon M; Comarmond C; Soriano A; Constans J; Alric L; Jego P; Busato F; Cabon M; Dhote R; Estibaliz L; Koné-Paut I; Landron C; Lavigne C; Lioger B; Michaud M; Ruivard M; Sacre K; Gottenberg JE; Gaches F; Goulenok T; Salvarani C; Cacoub P; Fain O; Saadoun D;
J Autoimmun; 2018 Jul; 91():55-60. PubMed ID: 29678346
[TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup.
Schmidt J; Kermani TA; Bacani AK; Crowson CS; Matteson EL; Warrington KJ
Arthritis Care Res (Hoboken); 2012 Jul; 64(7):1079-83. PubMed ID: 22328491
[TBL] [Abstract][Full Text] [Related]
12. Tocilizumab in treatment-naïve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial.
Mekinian A; Saadoun D; Vicaut E; Thietart S; Lioger B; Jego P; Bleibtreu A; Limal N; Connault J; Gottenberg JE; Lhorte P; Bertola JP; Delforge J; Ferreira-Maldent N; Perlat A; Talib Z; Vautier M; Savey L; Quiere I; Cacoub P; Fain O;
Arthritis Res Ther; 2020 Sep; 22(1):218. PubMed ID: 32943098
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study).
Nakaoka Y; Isobe M; Takei S; Tanaka Y; Ishii T; Yokota S; Nomura A; Yoshida S; Nishimoto N
Ann Rheum Dis; 2018 Mar; 77(3):348-354. PubMed ID: 29191819
[TBL] [Abstract][Full Text] [Related]
14. The effectiveness of tocilizumab and its comparison with tumor necrosis factor alpha inhibitors for Takayasu Arteritis: A systematic review and meta-analysis.
Misra DP; Singh K; Rathore U; Patro P; Tomelleri A; Campochiaro C; Agarwal V; Sharma A
Autoimmun Rev; 2023 Mar; 22(3):103275. PubMed ID: 36652977
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up.
Molloy ES; Langford CA; Clark TM; Gota CE; Hoffman GS
Ann Rheum Dis; 2008 Nov; 67(11):1567-9. PubMed ID: 18677012
[TBL] [Abstract][Full Text] [Related]
16. Biological treatments in giant cell arteritis & Takayasu arteritis.
Samson M; Espígol-Frigolé G; Terrades-García N; Prieto-González S; Corbera-Bellalta M; Alba-Rovira R; Hernández-Rodríguez J; Audia S; Bonnotte B; Cid MC
Eur J Intern Med; 2018 Apr; 50():12-19. PubMed ID: 29146018
[TBL] [Abstract][Full Text] [Related]
17. Refractory Takayasu arteritis successfully treated with rituximab: case-based review.
Mutoh T; Ishii T; Shirai T; Akita K; Kamogawa Y; Fujita Y; Sato H; Shirota Y; Fujii H; Harigae H
Rheumatol Int; 2019 Nov; 39(11):1989-1994. PubMed ID: 31388749
[TBL] [Abstract][Full Text] [Related]
18. Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis.
Campochiaro C; Tomelleri A; Sartorelli S; Cavalli G; De Luca G; Baldissera E; Dagna L
Semin Arthritis Rheum; 2020 Jun; 50(3):509-514. PubMed ID: 32088012
[TBL] [Abstract][Full Text] [Related]
19. Treatment of childhood-onset Takayasu arteritis: switching between anti-TNF and anti-IL-6 agents.
Sener S; Basaran O; Kaya Akca U; Atalay E; Kasap Cuceoglu M; Balik Z; Aliyev E; Bayindir Y; Batu ED; Hazirolan T; Bilginer Y; Ozen S
Rheumatology (Oxford); 2022 Nov; 61(12):4885-4891. PubMed ID: 35262635
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of tocilizumab for refractory Takayasu arteritis: a retrospective study and literature review.
Li H; Shuai Z
Heart Vessels; 2022 May; 37(5):884-894. PubMed ID: 34750666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
